SecBot SecBot
8-K ·Filed Aug 18, 2026

BMRN

BIOMARIN PHARMACEUTICAL INC
BULLISH
Impact 7/10
Horizondays Processed3mo ago SEC0001193125-26-354780
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The deal gains BioMarin a novel oral therapy for HPP, potentially expanding into a larger rare disease market. The all-cash structure and expected Q3 close limit balance-sheet risk. Watch for the closing, any regulatory updates on ALE-1, and updated 2026 guidance. The spin-out structure means no employee integration risk.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$66.99
T+0 close · Aug 18, 2026 · via day close
Latest settled
−14.72%
T+60 · $57.13
Vs SPY
−12.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 18 $66.99entry
  2. T+1 · 3mo ago +3.49%α +3.28% · $69.33
  3. T+5 · 3mo ago −1.30%α −1.10% · $66.12
  4. T+20 · 2mo ago −3.25%α −2.26% · $64.81
  5. T+60 · 6d ago −14.72%α −12.68% · $57.13
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioMarin (BMRN) entered into a definitive Share Purchase Agreement to acquire Alesta Therapeutics for $275 million upfront in cash, with up to $215 million in additional milestone-based payments, for a total potential consideration of up to $490 million. Alesta's lead asset is ALE-1, an oral small-molecule in a Phase 1/2a trial for hypophosphatasia (HPP). The deal is expected to close in Q3 2026, funded from cash on hand.

Key Financial Metrics

Deal Value
$490.0M
Deal Type
acquisition

Key Facts

  • BioMarin to acquire Alesta Therapeutics for $275M upfront cash, subject to customary post-closing purchase price adjustment.
  • Up to $215M in additional milestone payments tied to development and regulatory achievements for ALE-1.
  • ALE-1 is an orally active small molecule in Phase 1/2a for hypophosphatasia (HPP), a rare genetic bone disease with over 9,000 diagnosed patients in the US.
  • Alesta will spin out all non-ALE1 assets to a new entity (Anaheim SpinCo) prior to closing; no Alesta employees will join BioMarin.
  • Transaction expected to close in Q3 2026, funded with BioMarin's cash on hand.
  • Excluding the upfront consideration, the deal is expected to be modestly dilutive to 2026 financial results.
  • BioMarin plans to update full-year 2026 guidance after closing.

Financial Impact

Up to $490 million total potential consideration ($275M upfront + up to $215M milestones), all in cash. BioMarin intends to use cash on hand.

cashguidance

Risk Factors

  • Clinical and regulatory uncertainty: ALE-1 is still in Phase 1/2a; failure or delay would impair milestone value.
  • Milestone payments are contingent on future events; if milestones are not achieved, total consideration will be lower.
  • The spin-out of non-ALE1 assets must be completed before close; any complication could delay closing.
  • The upfront $275M outlay will reduce cash reserves, and the deal is expected to be modestly dilutive to 2026 EPS.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (33 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-354780
Document: d172628d8k.htm0001193125-26-354780
Document: d172628dex991.htm0001193125-26-354780
Document: 0001193125-26-354780-index-headers.html0001193125-26-354780
Document: 0001193125-26-354780-index.html0001193125-26-354780
Document: 0001193125-26-354780.txt0001193125-26-354780

Track record

16 reports on BMRN

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
  2. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
  3. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
  5. Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
  6. Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
  7. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  9. Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  10. Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 18, 2026